Remove first-year-b-pharmacy-notes
article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

A wave of blockbuster generic drugs launches, new brand drugs that address unmet needs, and legislation that would bring transparency to the pharmacy benefit manager (PBM) industry are just some of the developments that managed care pharmacy leaders are watching closely this year. billion in sales. This is a big one,” he added.

article thumbnail

9 Healthcare Marketing Trends to Embrace in 2023

Healthcare Success

We regularly come across new, well-funded telehealth-based providers, including addiction, mental health, men’s health, fertility, online pharmacies, B2B businesses, nutrition, primary care, and others. Consumer-First Content is Essential. Showing these individuals your facility is highly regarded as an essential first step.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

The question of whether biosimilars are interchangeable – and possibly even automatically substitutable at pharmacy level – remains a national prerogative, rather than one that can be mandated at an EU-level, as noted in the EMA’s guideline: 4. Are biosimilars interchangable? Internet] Available at: [link]. Available at: [link].

article thumbnail

Ep. 003 – Ritesh Patel Podcast Transcript

Pharma Marketing Network

And I’ll say, you know, it’s been very interesting over the last four years of following this, that we’re now seeing more and more the innovations really starting to hit the enterprise. That sounds like we’re hitting Series B or C on some of these companies. So thanks for the kind words.

Pharma 52
article thumbnail

Ep. 003 – Ritesh Patel Podcast Transcript

Pharma Marketing Network

And I’ll say, you know, it’s been very interesting over the last four years of following this, that we’re now seeing more and more the innovations really starting to hit the enterprise. That sounds like we’re hitting Series B or C on some of these companies. So thanks for the kind words.

Pharma 40
article thumbnail

Omri Shor

Cadensee

Show Notes. 13:51 Omri talks about the main things that he wishes he had known a few years ago working and navigating in healthcare organizations and pharma companies. 25:40 How has the business model of Medisafe shifted throughout the years? So our story starts about 8 years ago. That's 125,000 people a year.

Medical 52